FTC Warns Novo Nordisk’s $7B Weight-Loss Drug Deal May Be Illegal
The FTC has warned Novo Nordisk that its $7 billion offer to acquire weight-loss biotech Metsera may violate antitrust laws. The deal structure has ignited a bidding war with Pfizer, with both companies vying for dominance in the booming weight-loss drug market.